Arbutus Biopharma (ABUS) Change in Acquisitions & Divestments (2015 - 2026)

Arbutus Biopharma (ABUS) has reported Change in Acquisitions & Divestments for 10 consecutive years, with $16.0 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 65.27% year-over-year to $16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $125.2 million (down 27.84% YoY) and the FY2025 annual result came in at $155.3 million, down 5.69% from the prior year.
• Change in Acquisitions & Divestments fell to $16.0 million in Q1 2026 per ABUS's latest filing, from $23.8 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for ABUS reached as high as $56.7 million in Q4 2024 and fell as low as $2.0 million in Q1 2022.
• A 5-year average of $30.8 million and a median of $31.5 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments tumbled 90.17% — and 2023, when it soared 1750.0%.
• Year by year, Change in Acquisitions & Divestments stood at $26.0 million in 2022, then soared by 77.86% to $46.2 million in 2023, then rose by 22.58% to $56.7 million in 2024, then plunged by 57.96% to $23.8 million in 2025, then slumped by 32.86% to $16.0 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $16.0 million, $23.8 million, and $41.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.